Tags

Type your tag names separated by a space and hit enter

Bromocriptine: long-term low-dose therapy in Parkinson's disease.
Clin Neuropharmacol. 1986; 9(2):138-45.CN

Abstract

Low-dose bromocriptine therapy (average dose 14.5 mg/day at 2 years) produced significant improvement in 25 of 39 parkinsonian patients. Bradykinesia was less in de novo subjects; tremor and rigidity improved most in the levodopa subjects. Five of six patients improved after a low-dose bromocriptine drug "holiday." After the addition of bromocriptine any reductions in levodopa dosage were small, with repeated cuts made gradually over months preventing the deterioration commonly seen with larger sudden reductions in levodopa dosage. Five patients withdrew because of intolerable adverse effects, two because of worsening response. Adverse effects were mild and generally dose dependent, and in some patients they disappeared without reduction in continuing bromocriptine therapy. Eighty percent of those who tolerated bromocriptine maintained response over 2 years. Bromocriptine did not induce dyskinesia, the wearing-off response, or the on-off phenomenon in de novo subjects and was used as a first choice drug in these parkinsonian patients. Best results were obtained from a combination of bromocriptine and levodopa.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3708599

Citation

Teychenne, P F., et al. "Bromocriptine: Long-term Low-dose Therapy in Parkinson's Disease." Clinical Neuropharmacology, vol. 9, no. 2, 1986, pp. 138-45.
Teychenne PF, Bergsrud D, Elton RL, et al. Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clin Neuropharmacol. 1986;9(2):138-45.
Teychenne, P. F., Bergsrud, D., Elton, R. L., & Racy, A. (1986). Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clinical Neuropharmacology, 9(2), 138-45.
Teychenne PF, et al. Bromocriptine: Long-term Low-dose Therapy in Parkinson's Disease. Clin Neuropharmacol. 1986;9(2):138-45. PubMed PMID: 3708599.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bromocriptine: long-term low-dose therapy in Parkinson's disease. AU - Teychenne,P F, AU - Bergsrud,D, AU - Elton,R L, AU - Racy,A, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 138 EP - 45 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 9 IS - 2 N2 - Low-dose bromocriptine therapy (average dose 14.5 mg/day at 2 years) produced significant improvement in 25 of 39 parkinsonian patients. Bradykinesia was less in de novo subjects; tremor and rigidity improved most in the levodopa subjects. Five of six patients improved after a low-dose bromocriptine drug "holiday." After the addition of bromocriptine any reductions in levodopa dosage were small, with repeated cuts made gradually over months preventing the deterioration commonly seen with larger sudden reductions in levodopa dosage. Five patients withdrew because of intolerable adverse effects, two because of worsening response. Adverse effects were mild and generally dose dependent, and in some patients they disappeared without reduction in continuing bromocriptine therapy. Eighty percent of those who tolerated bromocriptine maintained response over 2 years. Bromocriptine did not induce dyskinesia, the wearing-off response, or the on-off phenomenon in de novo subjects and was used as a first choice drug in these parkinsonian patients. Best results were obtained from a combination of bromocriptine and levodopa. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/3708599/Bromocriptine:_long_term_low_dose_therapy_in_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -